Trump's 100% Drug Tariffs Are Now Law: What Canadian Benefit Plan Holders Need to Know

The U.S. administration's 100 percent tariff on imported pharmaceuticals became law, creating immediate cost implications for Canadian group benefit plan holders. Photo: iStock.

Tax & Wealth

Trump's 100% Drug Tariffs Are Now Law: What Canadian Benefit Plan Holders Need to Know

Apr 6, 2026 4 min The Tax & Wealth Desk

The Brief

Trump signed 100% tariffs on patented pharmaceuticals on April 2, targeting branded drugs from companies that have not struck pricing deals with his administration. Larger companies have 120 days before full implementation; smaller firms have 180 days.
Canada imports $8.76 billion in prescription drugs from the U.S. annually. To the extent those drugs pass through U.S. supply chains incorporating tariffed ingredients, costs will rise for Canadian payers regardless of where the drug is manufactured.
32% of active pharmaceutical ingredients used in North American drugs originate in China. U.S. tariffs on Chinese drug ingredients compound the pharmaceutical tariff, creating a layered cost structure that will work through benefit plan premiums over the next 12 to 18 months.
Employer-sponsored drug plans cover approximately 55% of Canadians. Job losses tied to tariff-driven economic weakness create a second risk: losing drug coverage simultaneously with rising out-of-pocket costs.
Generics and biosimilars are currently exempt from the 100% tariff, but the White House has indicated a reassessment in one year, creating planning uncertainty for benefit plan sponsors.

On April 2, one year after Liberation Day, President Trump marked the anniversary by signing a new round of tariffs on patented pharmaceuticals. The order imposes a 100% tariff on branded drugs and their active ingredients from companies that have not struck pricing deals with the administration. It is structured with escape valves, pathways to reduce the levy to 20% for companies committing to onshore U.S. manufacturing, full exemptions for those already in pricing negotiations with the Department of Health and Human Services. But for the broad universe of branded drug importers who fall outside those categories, a 100% tariff on patented pharmaceuticals is now law.

For Canadian advisors, the immediate question is not about drug pricing in the United States. It is about what this means for the cost of prescription drugs in Canada, for clients whose benefit plans cover those drugs, and for the planning assumptions that underpin group benefits, retirement income projections, and out-of-pocket health spending estimates.

How the Cost Transmission Works

The mechanism is indirect but real. Canada imports approximately $8.76 billion in prescription drugs from the U.S. annually. A significant portion of those drugs are branded products whose active pharmaceutical ingredients originate, at least in part, in China, which faces its own layered U.S. tariff regime. When U.S.-based manufacturers absorb tariff costs on Chinese ingredients and then export finished drugs to Canada, those cost increases follow the product. The chain is: Chinese API tariff, U.S. manufacturing cost increase, Canadian import price increase, benefit plan premium increase.

The University of Toronto research published in JAMA in early 2025 identified 411 drug products sold in the U.S. market that were manufactured in Canada, representing roughly $3 billion in U.S. pharmaceutical sales. Twenty-eight of those drugs have no alternative supplier. This cross-border interdependence cuts both ways: Canadian-made drugs face tariff exposure in the U.S. market, which pressures Canadian manufacturers and potentially reduces Canadian production capacity over time, while drugs flowing from the U.S. to Canada carry embedded cost increases from the American tariff regime.

The Benefit Plan Pressure Point

Approximately 55% of Canadians are covered by employer-sponsored drug plans. These plans are priced annually by insurers based on claims experience and formulary costs. The tariff cost transmission into benefit plan premiums is not instantaneous, it typically runs six to eighteen months behind the underlying price change, as formulary renegotiations and annual renewals absorb the increase. But the direction is clear, and plan sponsors who are renewing or repricing benefit plans in the second half of 2026 and into 2027 should expect drug costs to be a material line item in those discussions.

The second risk is job-related. Tariff-driven economic weakness has already produced softening in the Canadian labour market: the unemployment rate rose to 6.7% in February 2026, with the Bank of Canada noting that job gains from late 2025 were largely reversed in the first two months of this year. When employees lose jobs, they lose employer-sponsored drug coverage. During the COVID-19 pandemic, the share of Canadians without drug insurance surged, with disproportionate impact on lower-income earners. A tariff-induced layoff wave would reproduce that dynamic, compounded this time by higher underlying drug prices.

Generics, Biosimilars, and the One-Year Clock

The Trump order specifically exempts generic drugs and biosimilars from the 100% tariff, with a review scheduled in one year. Generic drugs represent a critical cost-management mechanism for Canadian benefit plans: substitution to generics when branded drugs come off patent is one of the primary levers plan sponsors use to control formulary costs. If that exemption expires or is curtailed in April 2027, the benefit plan cost environment becomes significantly more difficult. Plan sponsors and their advisors have roughly twelve months of runway to assess formulary exposure before that review date arrives.

For high-net-worth clients, the out-of-pocket dimension is also worth noting. Canadians who pay for specialty drugs, biologic therapies, or drugs not covered by provincial formularies directly face rising costs with no benefit plan buffer. At an individual level, the planning implication is a review of health spending accounts, medical expense tax credits, and the role of private supplemental coverage in the overall financial plan.

SOURCES White House Fact Sheet (pharmaceutical tariff proclamation, April 2, 2026), CNBC (Trump pharmaceutical tariff details), STAT News (Section 232 pharmaceutical tariff), The Conversation Canada (Canadian drug import exposure), Canada Healthwatch (tariff impact on Canadian drug access), CBC News (pharmaceutical tariff supply chain risks), CIDRAP/JAMA (University of Toronto drug supply analysis), Statistics Canada (employer drug plan coverage rates)

Educational content only. This article is published for informational and professional development purposes. It does not constitute investment advice, financial planning advice, or a recommendation to buy or sell any security. Canadian advisors should apply their own professional judgment. Full disclaimer.

Advisor Toolkits — Apr 6, 2026

🛡️ Respond ▼

What They're Feeling

Clients with chronic conditions, specialty drug needs, or family members on complex drug regimens are anxious. They may not have connected the pharmaceutical tariff news to their own situation yet, but a client who takes a biologic for rheumatoid arthritis, a specialty medication for a rare condition, or a high-cost branded drug not covered by their provincial formulary will have immediate questions when they see this story. Clients who are small business owners sponsoring benefit plans are concerned about another cost pressure on top of tariff-driven revenue disruption and oil-driven input cost increases.

What to Say

"The pharmaceutical tariff Trump signed last week is worth understanding, but I want to give you the right frame for it. The 100% tariff applies to branded, patented drugs from companies that haven't struck deals with the U.S. administration. Generics and biosimilars are currently exempt. The direct impact on what you pay in Canada won't be immediate, it runs through the benefit plan renewal cycle and the supply chain. The window is roughly six to eighteen months. What this means practically is that if you have a benefit plan as an employer, or if you pay for specialty drugs out of pocket, now is a good time to review your formulary exposure and make sure your coverage structure is optimized. I can help you think through whether there's anything specific to your situation that warrants attention."

Who's Affected

High impact: Small business owners who sponsor employee benefit plans and will face higher premium renewals in the next 12 to 18 months; clients who take branded specialty drugs not covered by provincial formularies and pay out of pocket or through private coverage. Medium impact: Clients approaching retirement who are planning to transition from employer-sponsored drug coverage to private supplemental coverage, as the cost of that coverage is likely to rise; clients with dependents on specialty medications. Lower impact: Clients whose drug needs are met primarily by generics, which are currently exempt from the 100% tariff.

Action Checklist

Review benefit plan renewal timelines for small business owner clients, flag those renewing in late 2026 or 2027 for a formulary cost conversation

Identify clients who pay for specialty or biologic drugs out of pocket and assess whether their health spending account (HSA) or medical expense tax credit strategy is optimized

For clients approaching retirement and losing employer drug coverage, reassess the cost assumptions in private supplemental plan projections, current pricing may underestimate future premiums

Note the April 2027 generic exemption review date in your planning calendar for affected clients

For clients with TFSA or RRSP room, the rising out-of-pocket health cost environment reinforces the case for maximizing tax-sheltered savings to fund future health spending flexibility

Follow-Up Email Template

Subject: Pharmaceutical tariffs and what they mean for your drug coverage

Hi [Client Name], You may have seen the news that President Trump signed 100% tariffs on patented pharmaceuticals on April 2. I wanted to give you a quick summary of what this means for Canadians specifically. The short version: The 100% tariff applies to branded, patented drugs. Generics and biosimilars are currently exempt. The cost impact on Canadian benefit plans and out-of-pocket payers will be gradual, running through supply chains and plan renewals over the next 12 to 18 months, not overnight. Why it matters for you: Canada imports $8.76 billion in prescription drugs from the U.S. annually. Cost increases in U.S.-sourced branded drugs will eventually work through to Canadian benefit plan premiums and private supplemental coverage costs. What we should look at: [Your benefit plan renewal timeline / Your specialty drug coverage and out-of-pocket exposure / Your health spending account utilization]. If any of these are relevant to your situation, I'd like to schedule a short review before your next plan renewal. [Your Name]

Compliance note: All scripts, checklists, and templates are provided for educational and professional development purposes only. They do not constitute approved marketing materials. Advisors are responsible for ensuring all client communications comply with applicable CIRO rules, provincial securities legislation, and their firm's compliance policies. Customize all templates before use. HDQ accepts no liability for the use of these materials.

🎯 Prospect ▼

Client Profiles to Target

High-priority: Small business owners with 5 to 50 employees who sponsor group benefit plans and have not recently reviewed their formulary structure or benefit cost trajectory; clients with chronic conditions or family members on specialty medications who pay out of pocket; individuals approaching retirement who will transition off employer drug coverage. Medium-priority: Any client who has mentioned health cost concerns in past conversations.

Opening Line

"Hi [Name], I wanted to reach out because there was a story last week that doesn't get much attention in general financial news but has real implications for Canadians with benefit plans or specialty drug needs. Trump signed 100% tariffs on patented pharmaceuticals on April 2. The cost won't hit immediately, but it will work through benefit plan renewals over the next year or two. Have you reviewed how your drug coverage is structured recently? I'd love to walk you through what to look for before your next renewal."

Value Proposition

Most advisors are not yet talking to clients about pharmaceutical tariffs. The headline is new, the cost transmission is gradual, and the connection to personal financial planning is not obvious without guidance. An advisor who surfaces this proactively and links it to specific planning actions demonstrates a quality of attention that most competitors will not match on this topic.

Discovery Questions

Do you or any family members take branded specialty medications? Are those costs covered by your benefit plan or paid out of pocket?
If you run a business, when does your group benefit plan renew? Have you reviewed your formulary costs recently?
Are you planning to retire within the next five years? Do you have a plan for drug coverage once you leave your employer plan?
Do you use a health spending account? Is it sized to absorb potential out-of-pocket drug cost increases?

Prospecting Email Template

Subject: A tariff story that matters for your benefit plan

Hi [Name], Most of the tariff coverage focuses on steel, auto parts, and oil. But on April 2, President Trump signed 100% tariffs on patented pharmaceuticals, a story that has direct implications for Canadians with employer drug plans, specialty medication costs, or retirement health coverage needs. Canada imports $8.76 billion in prescription drugs from the U.S. annually. The cost of those drugs is going to rise, and that increase will work through benefit plan premiums and private coverage costs over the next 12 to 18 months. If any of the following apply to you, it may be worth a 15-minute conversation: you run a business with a group benefit plan, you or a family member pays out of pocket for specialty medications, or you're approaching retirement and planning for drug coverage after your employer plan ends. Happy to walk you through what the tariff means specifically for your situation. [Your Name]

Compliance note: Prospecting communications are subject to CIRO rules on client communications and applicable anti-spam legislation (CASL). Ensure you have appropriate consent before sending unsolicited communications. All templates must be reviewed and approved by your firm's compliance department before use. HDQ accepts no liability for the use of these materials.